Miraculins Makes Unsolicited Bid to Acquire Dx Shop IBEX | GenomeWeb
NEW YORK (GenomeWeb News) — Biomarker research company Miraculins today said it has made an unsolicited offer to acquire Montreal-based IBEX, a cancer and arthritis diagnostics company.
 
"The cancer diagnostic programs of Miraculins and IBEX are extremely complementary, and future opportunities for our companies are enhanced by this transaction", Miraculins President Jim Charlton said in a statement.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.